Tandem Diabetes Care Inc (NASDAQ:TNDM)
| Market Cap | $1.40B+14.5% |
| Revenue (ttm) | $1.08B+6.8% |
| Net Income | -$49.23M+75.8% |
| EPS | -$0.72+76.4% |
| Shares Out | 69.79M |
| PE Ratio | n/a |
| Forward PE | 461.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,290,246.97 |
| Open | $19.00 |
| Previous Close | $17.51 |
| Day's Range | $18.53 - $20.11 |
| 52-Week Range | $12.26 - $29.65 |
| Beta | 1.60 |
| Analysts | Buy |
| Price Target | $23.19(+15.55%) |
| Earnings Date | Feb 18, 2027 |
About TNDM
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating TNDM in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 18, 2027Earnings report
$TNDM stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of TNDM by members of U.S. Congress
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Sep 29, 2026 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 3, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 3, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 2, 2026 |
| Josh GottheimerHouse / D | Purchase$1.00K – $15.00K | Sep 22, 2025 |
| Josh GottheimerHouse / D | Sale$1.00K – $15.00K | Mar 19, 2025 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 4, 2025 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 4, 2025 |
Recently reported changes in TNDM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TNDM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TNDM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TNDM Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TNDM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TNDM from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TNDM
| IJRiShares Core S&P Small-Cap ETF | $79.04M |
| VTIVanguard Morningstar Total Stock Market ETF | $35.67M |
| IWMiShares Russell 2000 ETF | $33.97M |
| VBVanguard Morningstar Small-Cap ETF | $25.56M |
| FESMFidelity Enhanced Small Cap ETF | $16.69M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $14.23M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from TNDM’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple FDA and regulatory approvals for new products, Q3 earnings beat, and strong product innovation offset valuation questions and past recall concerns.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| FDHT | FIDELITY DIGITAL HEALTH ETF | 1.78% |
| EDOC | Global X Telemedicine & Digital Health ETF | 1.77% |
| PEPT | REX Peptide ETF | 1.53% |
| XHE | State Street SPDR S&P Health Care Equipment ETF | 1.46% |
| FDLS | Inspire Fidelis Multi Factor ETF | 1.11% |
| HEAL | Global X HealthTech ETF | 1.09% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 0.69% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.48% |
| FYC | First Trust Small Cap Growth AlphaDEX Fund | 0.43% |
| EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | 0.36% |
| SLY | SPDR S&P 600 Small Cap ETF | 0.25% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.24% |
Weight is the stock’s share of each fund’s holdings.
